Zoetis Beheer
Beheer criteriumcontroles 4/4
De CEO Zoetis is Kristin Peck, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.24M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde $ 14.18M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 11 jaar.
Belangrijke informatie
Kristin Peck
Algemeen directeur
US$15.2m
Totale compensatie
| Percentage CEO-salaris | 7.9% |
| Dienstverband CEO | 4.8yrs |
| Eigendom CEO | 0.02% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 11yrs |
Recente managementupdates
Recent updates
Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet
Oct 26
Zoetis: A Solid Choice For The Young Dividend Growth Investor
Oct 09Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?
Oct 08Zoetis: Investing In Pet Health And Portfolio Wealth
Sep 26Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?
Sep 20There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price
Aug 30Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Jul 16Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Jul 03Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
Jun 11A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Jun 10Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth
May 23Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
May 22The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 04Zoetis: Long-Term Buy Despite Safety Concerns
May 03Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit
Apr 12Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Mar 03Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E
Jan 01Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Dec 06Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Nov 18Zoetis: High-Quality Compounder With A Reasonable Price After Earnings
Nov 09Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
Oct 26Zoetis Is An Impressive Healthcare Compounder
Sep 26Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$15m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$2b |
| Jun 30 2023 | n/a | n/a | US$2b |
| Mar 31 2023 | n/a | n/a | US$2b |
| Dec 31 2022 | US$14m | US$1m | US$2b |
| Sep 30 2022 | n/a | n/a | US$2b |
| Jun 30 2022 | n/a | n/a | US$2b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$13m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$10m | US$1m | US$2b |
| Sep 30 2020 | n/a | n/a | US$2b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$3m | US$690k | US$2b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$1b |
| Dec 31 2018 | US$3m | US$675k | US$1b |
| Sep 30 2018 | n/a | n/a | US$1b |
| Jun 30 2018 | n/a | n/a | US$1b |
| Mar 31 2018 | n/a | n/a | US$978m |
| Dec 31 2017 | US$3m | US$655k | US$864m |
Compensatie versus markt: De totale vergoeding ($USD 15.24M ) Kristin } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Kristin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Kristin Peck (53 yo)
4.8yrs
Tenure
US$15,237,853
Compensatie
Ms. Kristin C. Peck serves as an Independent Director at BlackRock, Inc. since joining on September 29, 2021. She has been the Chief Executive Officer of Zoetis Inc. since January 01, 2020 and its Director...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$15.24m | 0.018% $ 14.2m | |
| Executive VP & CFO | 3.4yrs | US$4.25m | 0.0034% $ 2.7m | |
| EVP, Chief Digital & Tech. Officer | 2yrs | US$2.69m | 0.0015% $ 1.2m | |
| Executive VP and President of Research & Development | 9.8yrs | US$2.44m | 0.00095% $ 757.9k | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP | less than a year | geen gegevens | 0.0035% $ 2.8m | |
| VP & Chief Communications Officer | no data | geen gegevens | geen gegevens | |
| Executive VP | less than a year | geen gegevens | 0.000020% $ 16.0k | |
| Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer | 4.2yrs | geen gegevens | 0.00015% $ 119.7k | |
| Executive VP and President of Global Manufacturing & Supply | 2.5yrs | geen gegevens | 0.00014% $ 111.7k | |
| Executive VP and Group President International Operations of Aquaculture & Global Diagnostics | no data | geen gegevens | 0.00043% $ 343.0k | |
| Executive VP and Head of Global Strategy | 2yrs | geen gegevens | 0.0011% $ 845.6k |
2.5yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ZTS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 5.1yrs | US$15.24m | 0.018% $ 14.2m | |
| Independent Director | 11.3yrs | US$370.00k | 0.0030% $ 2.4m | |
| Independent Non-Executive Chairman | 11.8yrs | US$490.00k | 0.0057% $ 4.6m | |
| Independent Director | 9.5yrs | US$340.00k | 0.0048% $ 3.9m | |
| Independent Director | 12.3yrs | US$340.50k | 0.0033% $ 2.6m | |
| Independent Director | 11.4yrs | US$340.00k | 0.0022% $ 1.7m | |
| Independent Director | 11.4yrs | US$365.00k | 0.0044% $ 3.5m | |
| Independent Director | less than a year | geen gegevens | 0.00017% $ 135.6k | |
| Independent Director | 11.8yrs | US$365.00k | 0.0034% $ 2.7m | |
| Independent Director | 10.7yrs | US$370.00k | 0.0022% $ 1.8m | |
| Independent Director | 2.3yrs | US$341.00k | 0.00023% $ 183.5k | |
| Independent Director | 3.9yrs | US$340.00k | 0.00049% $ 390.9k |
11.0yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ZTS zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).